



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8739

Senitiroh HAKOMORI, et al.

Appln. No.: 10/812,357

Group Art Unit: 1642

Confirmation No.: 4105

Examiner: Brandon J. Fetterolf

Filed: March 30, 2004

For: RM2 ANTIGEN (Beta1,4-GALNAc-6-SIALYL-LC) AS PROSTATE CANCER-ASSOCIATED ANTIGEN

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith with a copy of the International Search Report issued in the corresponding international application (PCT/US05/10221) dated October 20, 2006. The references cited in this International Search Report that are not listed on the attached PTO/SB/08 A & B (modified) are already of record in the present application.


INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/812,357

The present Information Disclosure Statement is being filed before a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore a Statement Under 37 C.F.R. § 1.97(e) is being submitted herewith. No fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


Mark L. Hayman
Registration No. 51,793

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: November 22, 2006

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8739

Senitiroh HAKOMORI, et al.

Appln. No.: 10/812,357

Group Art Unit: 1642

Confirmation No.: 4105

Examiner: Brandon J. Fetterolf

Filed: March 30, 2004

For: RM2 ANTIGEN (Beta1,4-GALNAc-DISIALYL-LC) AS PROSTATE CANCER-ASSOCIATED ANTIGEN

STATEMENT UNDER 37 C.F.R. § 1.97(e)


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

Respectfully submitted,


Mark L. Hayman
Registration No. 51,793

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: November 22, 2006

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Complete if Known

Application Number	10/812,357
Confirmation Number	4105
Filing Date	March 30, 2004
First Named Inventor	Senitiroh HAKOMORI
Art Unit	1642
Examiner Name	Brandon J. Fetterolf
Attorney Docket Number	A8739

1

of

1

[illegible][illegible]

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		SPECHT, et al., American Journal of Phathology 2001, Vol. 158, No. 2, page 419-429	In English
		SAITO, et al., International Journal of Cancer 2005, Vol. 115, pages 105-113	In English

Cite

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.

Translation⁶

SPECHT, et al., American Journal of Phathology 2001, Vol. 158, No. 2, page 419-429

In English

SAITO, et al., International Journal of Cancer 2005, Vol. 115, pages 105-113

In English

Date Considered

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.